FGH BIOTECH, INC.
FGH 10019, a small-molecule oral therapeutic targeting SREBP transcription factors for obesity treatment
- Sector
- Biotech
- Headquarters
- HOUSTON, TX
- Founded
- 2011
- Latest Form D
- $4M offered, Sep 2017
- Total capital
- $4.9M
- Federal grants
- $852K
- 1 award · 2015
- Rank in peer group#40 of 502
- Private capital raised
- $4M
- 2 Form D · last Sep 2017
- 110 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 6 pending · first 2018
- Rank in peer group#22 of 502
Capital timeline
Latest events
- Offering registeredForm D · SEC · 2nd filing$4M
- Offering registeredForm D · SEC · 1st filing$2.5M
- Federal grantHealth and Human S · Phase II · A New Mechanism For Treating Obesity$852K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
6months
from FGH BIOTECH, INC.’s first federal award to its first private round.
- First federal award · Apr 2015
- Health and Human S · $852K
- First Form D · Nov 2015
- $2.5M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grants#40 · top 8%
- Granted patents#22 · top 4%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Salih J WakilResearcherExecutive Officer, DirectorLinked by $852K in grants as PI
- Adam J KuspaDirectorNamed in SEC Form D filings
- Joe WakilExecutive Officer, DirectorNamed in SEC Form D filings
- Lufti J Abu-ElheigaExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 10- PendingDi-substituted Pyrazole Compounds For The Treatment Of DiseasesUSPTOApplication 17940640
- GrantedDi-substituted Pyrazole Compounds For The Treatment Of DiseasesUSPTOUS 11,497,738
- GrantedDi-substituted Pyrazole Compounds For The Treatment Of DiseasesUSPTOUS 11,339,142
Show all 10 patent records
- Di-substituted Pyrazole Compounds For The Treatment Of DiseasesApr 20, 2023 · Application 17940640Pending
- Di-substituted Pyrazole Compounds For The Treatment Of DiseasesNov 15, 2022 · US 11,497,738Granted
- Di-substituted Pyrazole Compounds For The Treatment Of DiseasesMay 24, 2022 · US 11,339,142Granted
- Compositions Of Fatostatin Based Heterocyclic Compounds And Uses ThereofJun 25, 2019 · US 10,328,064Granted
- Synthesis Of Fatostatin Based Polycyclic CompoundsJan 23, 2018 · US 9,873,689Granted
- Di-substituted Pyrazole Compounds For The Treatment Of DiseasesApplication PCTUS2017050562Pending
- Methods Of Using Inhibitors Of Srebp In Combination With Niclosamide And Analogs ThereofApplication 62784170Pending
- Di-substituted Pyrazole Compounds For The Treatment Of DiseasesApplication PCTUS2017030261Pending
- Synthesis Of Fatostatin Based Polycyclic CompoundsApplication PCTUS2015059411Pending
- Methods Of Using Inhibitors Of Srebp In Combination With Niclosamide And Analogs ThereofApplication PCTUS2019068445Pending
Related companies, and why
- ABILITA BIO, INC.Similar federal contract value in Biotech · null in contracts
- ACELOT, INC.Similar federal contract value in Biotech · null in contracts
- DeuteRx LLCSimilar federal contract value in Biotech · null in contracts
- Hillhurst Biopharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Larimar TherapeuticsSimilar federal contract value in Biotech · null in contracts
- ZYWIE LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .